STAT2h
FDA cuts, zombie biotechs, and too much weight loss?
On The Readout LOUD this week, STAT reporters discuss the FDA's staff cuts, how next-gen drugs may lead to too much weight ...
Hosted on MSN7d
Ultragenyx (RARE) Reports Q4 Loss, Tops Revenue Estimates
Ultragenyx (RARE) came out with a quarterly loss of $1.39 per share versus the Zacks Consensus Estimate of a loss of $1.24. This compares to loss of $1.52 per share a year ago. These figures are ...
Hosted on MSN1mon
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
From the intensifying battle over weight-loss drugs to the rise of AI to the uncertainty about President-elect Donald Trump's second term, biotech stocks won't be boring in 2025. Biotech may even ...